Patents by Inventor Donna D. Wei

Donna D. Wei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BENZOFURAN COMPOUNDS AS STING AGONISTS
    Publication number: 20240109899
    Abstract: The present invention is directed to compounds of formula (I) and (II), wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: February 3, 2022
    Publication date: April 4, 2024
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: BRIAN E. FINK, EMILY CHARLOTTE CHERNEY, LIPING ZHANG, JULIAN C. LO, GRETCHEN M. SCHROEDER, TRAM N. HUYNH, DONNA D. WEI, VIJAY T. AHUJA, CLAUDE A. QUESNELLE
  • AGONISTS OF ROR GAMMAt
    Publication number: 20220306630
    Abstract: The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: August 5, 2020
    Publication date: September 29, 2022
    Inventors: Lalgudi S. Harikrishnan, Peter Kinam Park, Zheming Ruan, Donna D. Wei, Daniel O'Malley, Honghe Wan, Ashok Vinayak Purandare, Brian E. Fink
  • Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses
    Patent number: 9902740
    Abstract: Macrocyclic benzodiazepine dimers having a structure represented by formula I where A and B are independently according to formulae Ia or Ib and the other variables in formulae I, Ia, and Ib are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used as the drug component in an antibody-drug conjugate (ADC).
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: February 27, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yong Zhang, Robert M. Borzilleri, Andrew J. Tebben, Erik M. Stang, Andrew F. Donnell, Gretchen M. Schroeder, Heidi L. Perez, Donna D. Wei
  • MACROCYCLIC BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, PREPARATION AND USES
    Publication number: 20170260205
    Abstract: Macrocyclic benzodiazepine dimers having a structure represented by formula I where A and B are independently according to formulae Ia or Ib and the other variables in formulae I, Ia, and Ib are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used as the drug component in an antibody-drug conjugate (ADC).
    Type: Application
    Filed: May 26, 2017
    Publication date: September 14, 2017
    Inventors: Yong ZHANG, Robert M. BORZILLERI, Andrew J. TEBBEN, Erik STANG, Andrew F. DONNELL, Gretchen M. SCHROEDER, Heidi L. PEREZ, Donna D. WEI
  • Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses
    Patent number: 9688694
    Abstract: Macrocyclic benzodiazepine dimers having a structure represented by formula I where A and B are independently according to formulae Ia or Ib and the other variables in formulae I, Ia, and Ib are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used as the drug component in an antibody-drug conjugate (ADC).
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: June 27, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yong Zhang, Robert M. Borzilleri, Andrew J. Tebben, Erik M. Stang, Andrew F. Donnell, Gretchen M. Schroeder, Heidi L. Perez, Donna D. Wei
  • IAP antagonists
    Patent number: 9603889
    Abstract: There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    Type: Grant
    Filed: October 1, 2013
    Date of Patent: March 28, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Kyoung S. Kim, Liping Zhang, Donna D. Wei
  • MACROCYCLIC BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, PREPARATION AND USES
    Publication number: 20160376288
    Abstract: Macrocyclic benzodiazepine dimers having a structure represented by formula I where A and B are independently according to formulae Ia or Ib and the other variables in formulae I, Ia, and Ib are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used as the drug component in an antibody-drug conjugate (ADC).
    Type: Application
    Filed: June 22, 2016
    Publication date: December 29, 2016
    Inventors: Yong ZHANG, Robert M. BORZILLERI, Andrew J. TEBBEN, Erik M. STANG, Andrew F. DONNELL, Gretchen M. SCHROEDER, Heidi L. PEREZ, Donna D. WEI
  • IAP antagonists
    Patent number: 9453048
    Abstract: There are disclosed compounds of formula (I) that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing said compounds.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: September 27, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert M. Borzilleri, Heidi L. Perez, Donna D. Wei, Kyoung S. Kim
  • Substituted sulfonamides useful as antiapoptotic Bcl inhibitors
    Patent number: 9346795
    Abstract: Disclosed are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: W and Q and G are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bcl-2 family antiapoptotic proteins for the treatment of cancer; and pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: May 24, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert M. Borzilleri, Zhen-Wei Cai, Andrew J. Tebben, Heidi L. Perez, Liping Zhang, Gretchen M. Schroeder, Donna D. Wei
  • IAP ANTAGONISTS
    Publication number: 20150238558
    Abstract: There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    Type: Application
    Filed: October 1, 2013
    Publication date: August 27, 2015
    Inventors: Kyoung S. Kim, Liping Zhang, Donna D. Wei
  • IAP ANTAGONISTS
    Publication number: 20150225452
    Abstract: There are disclosed compounds of formula (I) that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing said compounds.
    Type: Application
    Filed: August 6, 2013
    Publication date: August 13, 2015
    Inventors: Robert M. Borzilleri, Heidi L. Perez, Donna D. Wei, Kyoung S. Kim
  • SUBSTITUTED SULFONAMIDES USEFUL AS ANTIAPOPTOTIC BCL INHIBITORS
    Publication number: 20140135318
    Abstract: Disclosed are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: W and Q and G are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bcl-2 family antiapoptotic proteins for the treatment of cancer; and pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: May 23, 2012
    Publication date: May 15, 2014
    Applicant: Bristol-Myers Squibb Company
    Inventors: Robert M. Borzilleri, Zhen-Wei Cai, Andrew J. Tebben, Heidi L. Perez, Liping Zhang, Gretchen M. Schroeder, Donna D. Wei
  • Met kinase inhibitors
    Patent number: 7880004
    Abstract: The invention is directed to compounds that are useful for the treatment of cancer having the following Formula:
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: February 1, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert M. Borzilleri, Zhen-wei Cai, Donna D. Wei, John S. Tokarski
  • Pyrrolotriazine kinase inhibitors
    Patent number: 7102002
    Abstract: The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
    Type: Grant
    Filed: June 14, 2005
    Date of Patent: September 5, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Zhen-wei Cai, Louis J. Lombardo, Rajeev S. Bhide, Ligang Qian, Donna D. Wei, Stephanie Barbosa